Bevacizumab-Related Gastrointestinal Perforation in Hepatocellular Carcinoma Patient: A Case Report
<p>Introduction: Atezolizumab plus bevacizumab is widely recognized as the first-line treatment for advanced hepatocellular carcinoma (HCC). Bevacizumab, an anti-vascular endothelial growth factor (anti-VEGF), is effective against various cancers but carries a rare risk of gastrointestina...
Salvato in:
| Autori principali: | , , , |
|---|---|
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Karger Publishers
2025-12-01
|
| Serie: | Case Reports in Oncology |
| Accesso online: | https://karger.com/article/doi/10.1159/000549176 |
| Tags: |
Nessun Tag, puoi essere il primo ad aggiungerne!!
|